- Endonovo Therapeutics is developing bioelectronic devices that target patient pain, inflammation and wound recovery
- The company intends to get its flagship SofPulse device into 600 hospitals within the next 18 months as part of its bid to reduce post-operative drug dependence
- Drug dependence is regarded as a major contributor to a global opioid epidemic that has driven advocacy for less harmful pain drugs, increased governmental funding and new sentencing protocols for drug-related crimes
- The U.S. government has spent $2.4 billion during the past two years on addiction intervention amid statistics showing pain-killer death totals in the tens of thousands each year
Worldwide concerns about pain relief medication-induced addictions and deaths have led to a variety of societal changes during recent years, most notably driving the multinational advocacy for medical marijuana (cannabis) as a potential palliative without the degree of harmful effects from prescription and illegal narcotics, while also spawning increasing calls for governmental funding to fight addiction and change the judicial system’s approach to drug-related crimes. Amid some concerns about how private industry and governmental agencies are responding to the opioid epidemic/pandemic, Endonovo Therapeutics Inc. (OTCQB: ENDV) is advancing novel bioelectronic device solutions that are non-invasive and sidestep the drug issues entirely.
Endonovo Therapeutics is a commercial-stage developer of medical implements designed to provide proprietary, patent-protected electroceutical therapy for treating patient pain, inflammatory conditions, cardiovascular diseases and central nervous system disorders. The company’s flagship product, SofPulse, uses targeted electrical microcurrents to gently help reduce tissue swelling and speed up the natural recovery process.
Endonovo’s electroceutical therapy has received clearance for the palliative treatment of post-surgical pain and edema (swelling) from the U.S. Federal Drug Administration, has national coverage from the Centers for Medicare and Medicaid Services in chronic wound treatment and maintains a CE-mark certification that indicates conformity with European Economic Area health and environmental protection standards related to wound, pain and edema treatment.
On June 13, the company detailed its initial strategy for a national rollout of its SofPulse targeted pulsed electromagnetic field (tPEMF) therapy device to hospitals throughout the United States. According to the company’s news release, Endonovo plans to be in the evaluation stage with 600 hospitals within the next 18 months, employing 300 sales representatives (http://ibn.fm/gAHv2).
“After careful consideration and discussions, and in accordance with our internal budgets, we have reached the point at which we can confidently announce our national rollout plan and strategy,” CEO Alan Collier stated in a new release. “We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020. With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis.”
The federal government has provided at least $2.4 billion in grant money since 2017 to reduce opioid addiction, citing statistics reporting tens of thousands of drug addiction-related deaths each year, although reform advocates complain that the medical marijuana-fueled policy changes are too narrow in scope (http://ibn.fm/E67V1). Additional proposed legislation would provide a more widespread continuum of care for drug recovery, but at a cost of billions of dollars in taxpayer payouts (http://ibn.fm/5QOPp).
At the same time, media reports on new research are countering prior claims that states with legal medicinal marijuana had seen fewer opioid overdose deaths than states without legal medical cannabis, showing that addiction-related deaths in medical cannabis-legal states have actually been increasing (http://ibn.fm/X8gzJ) and indicating that “cannabinoids have demonstrated therapeutic benefits, but reducing population-level opioid overdose mortality does not appear to be among them,” according to a piece published by The Philadelphia Inquirer (http://ibn.fm/MPi3t).
Endonovo’s SofPulse device aims to elevate discussion of non-drug solutions to the addiction crisis (http://ibn.fm/tXlin), noting that, as the device reduces edema and pain levels, thereby decreasing the requirement for medication, “patients can move around sooner, which stimulates the body’s natural response to healing… (And) unlike prescription medications, SofPulse has no known side effects.” The company has filed an 8-K with the Securities and Exchange Commission, providing its new nationwide marketing plan with sales projections.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
